Fiscal Year:
2002
Title:
HIGH-THROUGHPUT DNA MICROARRAYS FOR INFLAMMATION
Agency:
HHS
Contract:
1R43AI051921-01
Award Amount:
$592,698.00
Abstract:
A quantitative high-throughput gene chip assay, ArrayPlateTM, based on nuclease protection has been developed for drug discovery. We will use this technology to develop two novel assays designed to
screen for compounds that affect the expression of transcription factors and
regulated genes involved in inflammation. Small changes in expression for any
of the genes will be quantified for cells exposed to putative drug candidates.
One assay will quantify two specific transcription factors involved in
inflammation and several genes they regulate (16 total). Another will test
expression of a wide panel of transcription factors implicated in the immune
response alongside factors controlling other physiological pathways (300
total). A model library of 2000 novel steroidal compounds will be screened.
ArrayPlateTM allows DNA array technology to be used in high throughput - with
accuracy and precision. Cells are lysed in the presence of nuclease protection
oligonucleotides, which hybridize to and protect all targeted mRNAs. After
nuclease digestion oligonucleotides bound stochiometrically to targeted
sequences are quantified on gene chips. Hybridization specificity is confirmed
within each sample. The method is sensitive enough to measure very rare mRNAs -
down to one mRNA molecule per cell, from 30,000 cells grown in a 96-well plate.
Small Business Information at Submission:
NEOGEN, LLC
NEOGEN, LLC BOX 64326, UNIVERSITY OF ARIZONA TUCSON, AZ 85728
EIN/Tax ID:
860897386
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned:
No
Minority-Owned:
No
HUBZone-Owned:
No